Takeda Pharmaceutical Co Ltd - Q1 FY2019 Summary
Business Context and Reporting Period
This Form 6-K reports the Quarterly Securities Report for Takeda Pharmaceutical Company Limited for the three-month period ended June 30, 2019 (First Quarter of the 143rd Business Term). The report was filed on August 9, 2019. The period marks the first full quarter of consolidated operations following the acquisition of Shire plc, which closed on January 8, 2019.
Key Financial Metrics
| Metric (JPY Billions) | Q1 FY2019 | Q1 FY2018 |
|---|---|---|
| Revenue | 849.1 | 449.8 |
| Operating Profit | 9.9 | 98.9 |
| Net Profit (Loss) | (20.6) | 78.1 |
| Net Profit Attributable to Owners | (20.7) | 78.2 |
| Basic EPS (JPY) | (13.28) | 100.05 |
| Operating Cash Flow | 120.8 | 40.5 |
| Cash and Equivalents (End of Period) | 593.7 | 231.5 |
| Total Assets | 13,550.4 | 4,159.6 |
| Total Equity | 4,874.5 | 2,066.6 |
Underlying Metrics (Non-IFRS):
- Underlying Revenue Growth: -0.8% (vs. pro-forma prior year)
- Underlying Core Operating Profit: 283.0 billion JPY
- Underlying Core Operating Profit Margin: 32.4%
- Underlying Core EPS: 123.56 JPY
Material Changes vs. Prior Period
The reported financial results were significantly impacted by the consolidation of Shire plc and associated purchase accounting adjustments.
- Revenue: Increased 88.8% to 849.1 billion JPY, driven primarily by 392.2 billion JPY in revenue from Shire products.
- Profitability: Operating profit collapsed 90.0% to 9.9 billion JPY, and the company reported a net loss of 20.6 billion JPY compared to a net profit of 78.1 billion JPY in the prior year.
- Key Expense Drivers:
- Amortization & Impairment: Increased 517.2% to 148.3 billion JPY. This includes 109.1 billion JPY in amortization of Shire intangible assets and a 15.6 billion JPY impairment charge for the terminated SHP616 AMR program.
- Cost of Sales: Increased 149.3% to 300.6 billion JPY, including an 84.5 billion JPY non-cash charge from the unwind of fair value step-up on inventory.
- Restructuring: Other operating expenses included 27.5 billion JPY in restructuring costs related to Shire integration.
- Balance Sheet: Total assets increased to 13.55 trillion JPY due to the Shire acquisition. Total equity decreased 289.1 billion JPY from the prior fiscal year-end, primarily due to dividend payments and currency translation adjustments.
Outlook, Commentary, and Risks
Management Commentary: Management emphasizes that reported results are distorted by non-recurring acquisition costs and purchase accounting effects. Underlying revenue growth was -0.8%, reflecting strong growth in 14 global brands (+22.2%) offset by generic erosion and competition in legacy products. The company highlighted a 32.4% underlying core operating profit margin, citing benefits from the Global Opex Initiative and Shire integration synergies.
R&D Pipeline Highlights:
- Oncology: Discontinued Phase 3 TOURMALINE-AL1 trial for NINLARO in AL amyloidosis; submitted application for Cabozantinib in renal cell carcinoma.
- GI: EMA and FDA accepted applications for subcutaneous ENTYVIO; VARSITY study showed superiority of vedolizumab over adalimumab in UC.
- Rare Diseases: TAKHZYRO data showed 80.1% decrease in attack rates; ADYNOVATE PROPEL study results presented.
Risks and Contingencies:
- Integration Risk: Ongoing challenges in integrating Shire operations and realizing cost synergies.
- Competition: Intensified competition and generic erosion affecting legacy products (e.g., LIALDA, ADVATE, CINRYZE).
- Regulatory: Risks associated with clinical trial outcomes and regulatory approvals for new indications.
- Divestitures: Agreed to divest XIIDRA and TACHOSIL; impact on future revenue streams.
Investor Verification Checklist
- Underlying vs. Reported: Verify the reconciliation between reported GAAP losses and the positive underlying core operating profit (283.0 billion JPY) to assess true operational performance.
- Amortization Impact: Confirm the magnitude of non-cash amortization charges (109.1 billion JPY) related to Shire intangible assets and their duration.
- Product Mix Shift: Analyze the specific revenue contributions of Shire products (392.2 billion JPY) versus legacy Takeda products to understand the new revenue base.
- Debt Servicing: Review the increase in finance expenses (211.4% increase) and the company's ability to service debt incurred for the Shire acquisition.
- Divestiture Timeline: Monitor the completion dates and financial impact of the agreed divestitures of XIIDRA and TACHOSIL.